In vitro, transcript elongation by RNA polymerase II is impeded by DNA sequences, DNA-bound proteins, and small ligands. Transcription elongation factor SII (TFIIS) assists RNA polymerase II to transcribe through these obstacles. There is however, little direct evidence that SII-responsive arrest sites function in living cells nor that SII facilitates readthrough in vivo. Saccharomyces cerevisiae strains lacking elongation factor SII and/or containing a point mutation in the second largest subunit of RNA polymerase II, which slows the enzyme's RNA elongation rate, grow slowly and have defects in mRNA metabolism, particularly in the presence of nucleotide-depleting drugs. Here we have examined transcriptional induction in strains lacking SII or containing the slow polymerase mutation. Both mutants and a combined double mutant were defective in induction of GAL1 and ENA1. This was not due to an increase in mRNA degradation and was independent of any drug treatment, although treatment with the nucleotide-depleting drug 6-azauracil exacerbated the effect preferentially in the mutants. These data are consistent with mutants in the Elongator complex, which show slow inductive responses. When a potent in vitro arrest site was transcribed in these strains, there was no perceptible effect upon mRNA accumulation. These data suggest that an alternative elongation surveillance mechanism exists in vivo to overcome arrest.
Several factors have been identified that act as transcription elongation factors in vitro.One of the best studied is transcription elongation factor SII (also known as TFIIS), which facilitates readthrough of transcription arrest sites and other blocks to RNA polymerase II (pol II) 1 elongation in vitro (1, 2). SII acts by binding to pol II and activating an intrinsic RNA cleavage activity within the enzyme that shortens the newly transcribed RNA and allows re-extension of the arrested transcript past the block to elongation (1, 2).The transcription arrest process has been difficult to study in vivo, due in part to the rapid processing of primary transcripts and degradation of incomplete transcripts. Sensitivity of yeast to nucleotide-depleting drugs such as 6-azauracil (6AU) and mycophenolic acid has served as a phenotypic indicator of yeast with mutations in genes encoding pol II subunits and transcription elongation factors, including RPB1, RPB2, RPB6, RPB9, DST1, ELP1, ELP3, SPT4, SPT5, SPT6, SPT16,. This drug sensitivity is thought to result from stress upon the elongation machinery due to a reduction in the intracellular pools of nucleotides used for RNA synthesis (3,8). It is well known that, in vitro, a low concentration of nucleotide substrates causes pol II to transcribe at a slower rate, become arrested more often, and therefore be dependent upon SII for efficient elongation (4, 14 -17). Hence, upon drug treatment, yeast may become more dependent upon efficient transcript elongation by pol II. Nevertheless, not all 6AU-sensitive mutants carry mutations in genes that are obviously related to tra...